Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Flonoltinib Pharmacokinetics in Healthy Subjects
NCT07193576Phase 1Completed
- Sponsor
- Zenitar
- Start
- Aug 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of flonoltinib in myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) (2 arms), sponsored by Zenitar. Primary endpoints: Maximum Plasma Concentration at Day 11, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at Day 11 and 3 more. Started Aug 2024; status: completed.
02
Drugs
flonoltinib
03
Conditions
myelofibrosis (MF)polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT07193576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193576.